<![CDATA[FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC]]>
RegulatoryapprovedZidesamtinibPositive
AI Analysis
Summary
The FDA has approved Zidesamtinib for the treatment of pretreated ROS1-positive non-small cell lung cancer, supported by data from the ARROS-1 phase 1/2 trial.
Clinical Trial Data
Phase
1/2
Outcome Details
FDA approval for pretreated ROS1-positive NSCLC
Importance:8/10
Sentiment:
0.90
FDA approvaloncologyROS1-positive NSCLCtargeted therapyARROS-1 trial
Related Companies
Read the original article
Published by Cancer Network on July 22, 2026 5:26 PM